期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

耐药基因蛋白在不同分子亚型乳腺癌中的表达及其与雌孕激素受体和人表皮生长因子受体2的关系 被引量：7

原文传递
导出
摘要 乳腺癌耐药为多种耐药基因参与、不同机制共同作用的结果,涉及P-糖蛋白（P-gp）、谷胱甘肽-S-转移酶（GST-π）、DNA拓扑异构酶（TOPO-Ⅱ）等.在本研究中,我们探讨了不同分子亚型中乳腺癌耐药基因蛋白的表达及其与激素受体和人表皮生长因子受体2 （human epidermal growth factor receptor 2,HER-2）的关系。
作者 姚宇锋 唐金海 马蓉 徐新宇 秦建伟
机构地区 南京
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2014年第10期771-772,共2页 Chinese Journal of Oncology
基金 江苏省自然科学基金（BK20131016） 江苏省333高层次人才培养工程（BRA2011214）
关键词 乳腺肿瘤 多药耐药相关蛋白质类 分子亚型 雌激素受体 孕激素受体 Breast neoplasms Multidrug resistance-associated proteins Molecular subtypes Estrogen receptor Progesterone receptor
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献41

  • 1袁建辉,贺智敏,余艳辉,陈主初.Tet调控的乳腺癌耐受蛋白表达细胞系的建立及功能研究[J].癌症,2004,23(10):1127-1133. 被引量：7
  • 2丁渭,郑春艳,贺智敏,吕辉,刘孝荣,余艳辉,陈主初.HER2介导乳腺癌细胞多药耐药的作用及机制[J].国际病理科学与临床杂志,2005,25(5):381-385. 被引量：12
  • 3杨黎,朱霞,冉立.HER-2、PCNA、Bcl-2、Bax在乳腺癌组织中的表达与预后的关系[J].癌症,2007,26(7):756-761. 被引量：17
  • 4Burger H,Foekens JA,Look MP,et al.RNA expression of breast cancer resistance protein,lung resistance-related protein,multidrug resistance-associated proteins 1 and 2,and multidrug resistance gene 1 in breast cancer:correlation with chemotherapeutic response.Clin Cancer Res,2003,9:827-836.
  • 5徐兵河.乳腺癌.北京:北京医学出版社,2008:44.
  • 6Doyle LA,Yang W,Abruzzo LV,et al.A multidrug transporter from human MCF-7 breast cancer.Proc Natl Sci U S A,1998,95:15665-15670.
  • 7Rybarova S,Hodorova I,Hajdukova M,et al.Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters.Neoplasma,2006,53:128-135.
  • 8Trock BJ,Leonessa F,Clarke R.Multi-drug resistance and breast cancer:a meta-analysis of MDR1 and its functional significance.J Natl Cancer Inst,1997,89:917-931.
  • 9Trock BJ, Leonessa F, Clarke R. Muhidrug resistance in breast a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst, 1997, 89:917-931.
  • 10Chung HC, Rha SY, Kim JH, et al. P-glycoprotcin: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat, 1997, 42:65-72.

共引文献22

同被引文献61

  • 1Rebecca S,Deepa MA,Ahmedin DV.Cancer statistics,2012[J].A Cancer J Clin,2012,62(1):10-29.
  • 2Onitilo AA,Engel JM,Greenlee RT,et al.Breast cancer subtypes based on ER/PR and Her-2 expression:compa Fisoll of clinicopathologic features and survival[J].Clin Med Res,2009,7(12):4-13.
  • 3Kaneko N,Yamanaka K,Kita A,et al.Synergistic antitumor activities of sepantronium bromide(YM155),a survivin suppressant,in combination with microtubule-targeting agents in triple-negative breast cancer cells[J].Biol Pharm Bull,2013,36(12):1921-1927.
  • 4Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypesdealing with the diversity of breast cancer:highlights of the International Export Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
  • 5Nestal de Moraes G,Castro CP.The pterocarpanquinone LQB-118induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets Fox O3a and Fox M1 transcription factors[J].Int J Oncol,2014,45(5):1949-1958.
  • 6Chert XS,Ma CD,Wu TY,et al.Molecular subtype approximated by quantitative estrogen receptor,Progestemne receptor and Her-2can predict the prognosis of breast cancer[J].Tumori,2010,96(1):103-110.
  • 7Long M,Hao M,Dong K,et al.AEG-1 overexpression is essential for maintenance of malignant state in human AML cells via up-regulation of Akt1 mediated by AURKA activation[J].Cell Signal,2013,25(6):1438-1446.
  • 8RAUCH G M, HOBBS B P, KUERER H M, et al. Microcalcifica- tions in 1,657 patients with pure ductal carcinoma in situ of the breast: corrdation with clinical, histopathologic, biologic features, and local recurrence[J]. Ann Surg Oncol, 2015, 9(28): 112-114.
  • 9WINTON L M, NODORA J N, MARTINEZ M E, et al. Factors associated with surgical management in an underinsured, safety net population[J]. Surgery, 2015, 3(15): 655-658.
  • 10ONITILO A A, ENGEL J M, GREENLEE R T, et al. Breast cancer subtypes based on ER/PR and Her-2 expression: compa Fisoll of clinic-opathologic features and survival[l]. Clin Med Res, 2009, 7(12): 4-13.

引证文献7

二级引证文献38

中华肿瘤杂志
2014年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部